[
    [
        {
            "time": "",
            "original_text": "二探“首家”科创药企微芯生物：单一产品遇内外伏兵，闯关前夜临定价难题",
            "features": {
                "keywords": [
                    "微芯生物",
                    "科创板",
                    "单一产品",
                    "内外压力",
                    "定价难题"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "二探“首家”科创药企微芯生物：单一产品遇内外伏兵，闯关前夜临定价难题",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]